Status and phase
Conditions
Treatments
About
This is a Phase I, single-center, double blind, placebo-controlled, parallel-group, randomized study designed to evaluate the PK, cardiodynamic ECG effects, safety, and tolerability of 2 single ascending oral doses of linaprazan glurate. The study will explore the PK properties of linaprazan glurate and linaprazan as well as the cardiodynamic ECG effects, safety, and tolerability after the administration of single doses (300 mg, 600 mg, 200 mg and a final dose level of maximum 400 mg) of linaprazan glurate, using 25 mg base formulation (300 mg and 600 mg doses) and 25 mg and 100 mg HCl formulation (200 mg and final dose level of maximum 400 mg) oral tablets.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Main inclusion Criteria:
Main exclusion criteria:
Primary purpose
Allocation
Interventional model
Masking
113 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Simon Rubinstein, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal